Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab and Trastuzumab with XELOX in HER2+ Resectable Gastric/GEJ Cancer
NCT04661150Phase 2Completed
- Sponsor
- Roche
- Start
- Mar 2021
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in gastric cancer (GC) and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Roche. Primary endpoint: Pathological Complete Regression Rate at 16 months. Started Mar 2021; status: completed.
02
Drugs
atezolizumab
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT04661150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04661150.